-  Unilateral or bilateral intraocular retinoblastoma
  -  Diagnosis between the ages of 0 - 17.99 years
  -  Diagnosis on or after January 1, 2008
  -  No exclusions based on primary or secondary treatment modalities
  -  Retrospective group patients must be ≥ 6 months post end of treatment at study entry
       -  For those already at this timepoint, they are now eligible
       -  For those in treatment, or otherwise not yet at this timepoint, they are eligible once at they are ≥ 6 months post end of treatment
       -  Prospective group patients must not have begun treatment
  -  Patients with diminished capacity will not be enrolled.
  -  Language: Patients must be able to communicate in English, French, or Spanish
  -  Sibling Cohort: One sibling, not affected by retinoblastoma will be enrolled, preference for the sibling closest in age to the RB patient.
  -  Regulatory Requirements: All patients and/or their parents or legal guardians must sign a written informed consent. All institutional, FDA, and NCI requirements for human studies must be met.